Insulin-associated peptides with effects on cerebral health

Details Insulin-associated peptides with effects on cerebral health Insulin-associated peptides with effects on cerebral health

2003-05-06

2010-02-02

Kemmerer, Elizabeth C. (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013800, C514S011400

Reexamination Certificate

active

07655619

ABSTRACT:
The present invention provides compositions and methods for ameliorating neurological, attention, or memory disorders and improving learning and cognition through the delivery of insulin A-chain and analogs thereof to a subject. Insulin A-chain, peptides comprising the 21 amino acid sequence GIVEQ CCASV CSLYQ LENYC N (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of insulin A-chain peptide or a functional analogs thereof.

REFERENCES:
patent: 4659696 (1987-04-01), Hirai et al.
patent: 5725860 (1998-03-01), Elliott
patent: 5747445 (1998-05-01), Backstrom et al.
patent: 6313093 (2001-11-01), Frey, II
patent: 6335361 (2002-01-01), Hamilton
patent: 6407061 (2002-06-01), Frey, II
patent: 19826628 (2000-07-01), None
patent: 00/61177 (2000-10-01), None
Bullesbach EE et al. Functional importance of the A chain loop in relaxin and insulin. J Biol Chem, 1994; 269(18): 13124-13128.
Diaz Brinton R and Yamazaki RS. Advances and challenges in the prevention and treatment of Alzheimer's disease. Pharm Res, 1998; 15(3): 386-398.
Fehm HL et al. Manipulating neuropeptidgergic pathways in humans: a novel approach to neuropharmacology? Eur J Pharm, 2000; 405: 43-54.
Feigin A and Zgaljardic D. Recent advances in Huntington's disease: Implications for experimental therapeutics. Curr Opin Neurol, 2002; 15: 483-489.
Shao Z et al. Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations. Pharm Res, 1992; 9(9): 1157-1163.
Steece-Collier K et al. Etiology of Parkinson's disease: Genetics and environment revisited. Proc Natl Acad Sci USA, 2002; 99(22): 13972-13974.
Reger MA et al. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiology Aging, 2006; 27:451-458.
Wan et al. Biochem. 2005, 44:5000-5016.
Yan et al. Science, 2000, 290(5491):523-527.
Liu XF et al. J Neurological Sci. 2001, 187:91-97.
Sasaki N et al. J Biol Chem. 1985, 260(17):9793-9804.
Brandt, Burkhard et al. “Early Placenta Insulin-Like Growth Factor (pro-EPIL) is Over-Expressed And Secreted By c-erbB-2-Positive Cells With High Invasion Potential,” Cancer Research, pp. 1020-1024 (2002).
Claeys, Ilse et al. “Insulin-Related Peptides And Their Conserved Signal Transduction Pathway,” Peptides, vol. 23, pp. 807-816 (2002).
Gasparini, Laura et al. “Does Insulin Dysfunction Play A Role In Alzheimer's Disease,” Trends in Pharmacological Sciences, vol. 23, No. 6, pp. 288-293 (2002).
Park, Collin R. et al. “Intracerebroventricular Insulin Enhances Memory In A Passive-Avoidance Task,” Physiology & Behavior, vol. 68, pp. 509-514 (2000).
Tatar, Marc et al. “The Endocrine Regulation of Aging by Insulin-Like Signals,” Science, vol. 299, pp. 1346-1351, (2003).
Zhao, Wei-Qin and Alkon, Daniel L. “Role of Insulin And Insulin Receptor In Learning And Memory,” Molecular and Cellular Endocrinology, vol. 177, pp. 125-134 (2001).
Cooper, G.J.S. et al. “Purification and Characterization of a Peptide From Amyloid-Rich Pancreases of Type 2 Diabetic Patients,” Proc. Natl. Acad., Sci USA, vol. 84, pp. 8628-8632 (1987).
O'Brien, T.D. “Pathogenesis of Feline Diabetes Mellitus,” Molecular and Cellular Endocrinology, vol. 197, pp. 213-219, (2002).
Zhang, Yi et al. “Nasal Absorption Enhancement of Insulin By Sodium Deoxycholate In Combination With Cyclodextrins,” Acta Pharmacol Sin, vol. 22, No. 11, pp. 1051-1056 (2001).
Craft et al., “Enhancement of Memory In Alzheimer Disease With Insulin And Somatostatin, But Not Glucose”, Arch Gen Psychiatry, vol. 56, pp. 1135-1141.
Kern et al., “Improving Influence Of Insulin On Cognitive Functions In Humans”, Neuroendocrinology, vol. 74, pp. 270-280, 2001.
European Search Report dated Jul. 31, 2009 for European Patent Application No. 03 74 7673.6.

Affiliated with

Also associated with

Rating

Insulin-associated peptides with effects on cerebral health does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Insulin-associated peptides with effects on cerebral health, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin-associated peptides with effects on cerebral health will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4192967